Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313–9.e1.
2. van Heuven WA, Hayreh MS, Hayreh SS. Experimental central retinal vascular occlusion. Blood-retinal barrier alterations and retinal lesions. Trans Ophthalmol Soc U K (1962). 1977;97:588–618.
3. Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome. Prog Retin Eye Res. 2014;41:1–25.
4. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Group SI. Month 60 outcomes after treatment initiation with anti-vascular endothelial growth factor therapy for macular edema due to central retinal or hemiretinal vein occlusion. Am J Ophthalmol. 2022;240:330–41.
5. Iftikhar M, Mir TA, Hafiz G, Zimmer-Galler I, Scott AW, Solomon SD, et al. Loss of peak vision in retinal vein occlusion patients treated for macular edema. Am J Ophthalmol. 2019;205:17–26.